Slide 1: 2009 Preliminary results
Milan, Conference Call, 11 February 2010 2009 Preliminaryy results Outlook for 2010
Slide 2: 2009 Highlights
2009 HIGHLIGHTS • Revenue € 747.5 million, up 8.4%, international sales grow by 10.6% • Operating p g income ((EBIT)) € 162.2 million,, up p 12.1% • Net Income € 110.6 million, up 10.1% • Acquisition A i iti off H Herbacos-Bofarma b B f in i th the C Czech hRRepublic bli • Urorec ® /Silodyx ® (silod
Slide 3: Composition of Revenue
COMPOSITION OF REVENUE (million Euro) 2009 2008 Change % Italyy 210.6 201.6 4.5 France 162.4 156.7 3.6 Germany 65.8 58.2 13.0 Portugal 36 8 36.8 43 2 43.2 (14 8) (14.8) Spain 30.9 28.4 8.7 United Kingdom 15.1 14.5 4.5 Other Western European countries 15.6 13.1 18.7 Russia, Turkey, other CEE countrie
Slide 4: Composition of Pharmaceutical Revenue
COMPOSITION OF PHARMACEUTICAL REVENUE Portugal 5.1% Spain 4.3% Germany 9.1% UK 2.1% Other W. European countries 2.2% France 22.5% Russia, Turkey, other CEE 7.6% Other international sales 17.8% Pharmaceutical chemicals 3.6% Italy 29.2% Pharmaceuticals 96.4% Data: Full year 2009 Total revenue € 747.5
Slide 5: Main Product Sales
MAIN PRODUCT SALES (million Euro) 2009 2008 Change % Zanidip® (lercanidipine) 214 9 214.9 201.6 6.6 Zanipress® (lercanidipine+enalapril) 20.8 6.9 201.9 Other corporate products 37.1 26.8 38.2 Orphan drugs 48.9 43.9 11.4 4
Slide 6: Full Year 2009 Results
FULL YEAR 2009 RESULTS (million Euro) 2009 2008 Change % Revenue 747.5 689.6 8.4 Gross Profit 511.9 467.4 9.5 as % of revenue 68.5 67.8 SG&A Expenses 267.4 253.6 5.5 as % of revenue 35.8 36.8 R&D & Expenses pe ses 69.4 58.9 58 9 18.0 80 as % of revenue 9.3 8.5 Other Income (Expense), net (12.8) (10.
Slide 7: Net Financial Position and Shareholder's Equity
NET FINANCIAL POSITION AND SHAREHOLDER’S EQUITY (million Euro) 31 Dec 2009 31 Dec 2008 Change Cash and short-term financial 93.8 95.0 (1.2) investments Bank overdrafts and short-term (28.9) (90.8) 62.0 loans Loans – due within one year (2 4) (2.4) (2.2) (0.2) Loans – due after one year (82.2) (82.9)
Slide 8: 2010 Targets
2010 TARGETS 2009 2010 Actual Targets (million Euro) Revenue 747.5 ~700 Operating income (EBIT) 162.2 ~140 N t Income Net I 110 6 110.6 ~95 95 7
Slide 9: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finan